Compared with the anti-EpCAM-MN enrichment approach, the combination of anti-EpCAM-MNs and anti-FRα-MNs in parallel allowed the capture of five types of NSCLC cells with higher efficiency (P < 0.01). The gene discussed is EPCAM; the disease is non-small cell lung carcinoma.